Efficacy and safety of dapagliflozin over 1 year as add‐on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial

Aims To evaluate the efficacy and safety of dapagliflozin as add‐on to insulin in J apanese patients with type 2 diabetes. Materials and methods Insulin‐treated J apanese patients were randomized to 5 mg dapagliflozin or placebo during a 16‐week double‐blind treatment period. Both groups then received dapagliflozin 5 or 10 mg (the dose was increased at or after week 24 if glycated haemoglobin [ HbA1c ] at the previous visit was >7.5%) during...